Parsey Merdad

October 15, 2026

Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.

October 16, 2026

Gilead Signs $1.9B Deal With Vir For T-Cell Engagers. Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.

September 25, 2026

Goldman Sachs reinstates Sell rating on SGMT with $7 target. Goldman Sachs has reinstated a Sell rating on Sagimet Biosciences, setting a price target of $7. This move stands in contrast to the average analyst target of $29.60, highlighting a significant divergence in expert opinions. The stock is currently trading near its 52-week low of $4.50, reflecting the bearish sentiment associated with the new rating.